Stock ADOC ADOCIA
Add to a list
To use this feature you must be a member
Log inSign up

Adocia Stock

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:10 2024-05-28 am EDT 		5-day change 1st Jan Change
8.82 EUR -0.68% Intraday chart for Adocia -6.57% -23.57%
May. 14 Adocia SA announced that it has received ?2 million in funding CI
Apr. 24 Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 50M 54.28M Sales 2025 * 86M 93.35M Capitalization 127M 138M
Net income 2024 * 26M 28.22M Net income 2025 * 40M 43.42M EV / Sales 2024 * 2.09 x
Net cash position 2024 * 22.5M 24.42M Net cash position 2025 * 62.3M 67.63M EV / Sales 2025 * 0.75 x
P/E ratio 2024 *
2.37 x
P/E ratio 2025 *
1.58 x
Employees 78
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.51%
More Fundamentals * Assessed data

Chart Adocia

Dynamic Chart

Latest news about Adocia

Adocia SA announced that it has received ?2 million in funding CI
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adocia: announces fund-raising CF
Adocia SA announced that it expects to receive ?2 million in funding CI
Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes CI
Adocia: positive study data for BC Combo CF
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Adocia: refinancing operations completed CF
Adocia SA announced that it has received ?9.999993 million in funding from Bpifrance Investissement SAS, Vester Finance SA CI
Adocia: exclusive right to negotiate M1Pram with Sanofi CF
Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug MT
Adocia Signs an Exclusivity Agreement with Sanofi for M1Pram CI
Adocia SA announced that it expects to receive €10 million in funding CI
Adocia Requests Trading Halt on Euronext Paris MT
Adocia: listing suspended pending a press release CF
More news

Press releases Adocia

Adocia : Document AMF CP. 2024E967706 PU
ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 13th, 2024 in Paris BU
Adocia : Document AMF CP. 2024E967033 PU
Adocia : List of other corporate offices currently held by the Directors and Board PU
ADOCIA Reports First Quarter 2024 Financial Results and Provides a Business Update BU
More press releases

News in other languages on Adocia

Adocia : Auditors’ report on the resolutions (French only)
ADOCIA annonce la tenue de son assemblée générale annuelle le 13 juin 2024 à Paris
Adocia : Document AMF CP. 2024E966402
Adocia : Document AMF CP. 2024E965846
Adocia: 10,2 millions d'euros de trésorerie au 31 mars, visibilité jusqu'au troisième trimestre 2025
More news

Quotes and Performance

1 day-0.68%
1 week-6.57%
Current month+5.50%
1 month+4.63%
3 months-9.35%
6 months+12.36%
Current year-23.57%
More quotes

Highs and lows

1 week
8.61
Extreme 8.61
9.53
1 month
8.20
Extreme 8.2
9.99
Current year
7.89
Extreme 7.89
12.40
1 year
3.59
Extreme 3.59
16.16
3 years
2.75
Extreme 2.745
16.16
5 years
2.75
Extreme 2.745
22.60
10 years
2.75
Extreme 2.745
94.24
More quotes

Managers and Directors - Adocia

Managers TitleAgeSince
Olivier Soula FOU
 Founder 53 05-12-15
Gérard Soula FOU
 Founder 78 05-12-15
Valérie Danaguezian DFI
 Director of Finance/CFO - 05-12-31
Members of the board TitleAgeSince
Gérard Soula FOU
 Founder 78 05-12-15
Katherine Bowdish BRD
 Director/Board Member 67 21-05-20
Ekaterina Smirnyagina BRD
 Director/Board Member 58 13-06-17
More insiders

Quotes

Date Price Change Volume
24-05-28 8.82 -0.68% 74,460
24-05-27 8.88 -1.99% 104,262
24-05-24 9.06 -0.22% 48,863
24-05-23 9.08 -1.41% 50,310
24-05-22 9.21 +0.44% 76,398

Real-time Euronext Paris, May 28, 2024 at 11:35 am EDT

More quotes

Company Profile

Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Sector
Biotechnology & Medical Research
Calendar
2024-06-13 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Adocia

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.82 EUR
Average target price
9.7 EUR
Spread / Average Target
+9.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADOCIA Stock Adocia
-23.57% 139M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 106B
BIONTECH SE Stock BioNTech SE
-10.84% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ADOC Stock